Related Experiment Videos
Proteasome-dependent degradation of p27/kip1 in gliomas
R Piva1, I Cancelli, P Cavalla
1Department of Neuroscience, University of Turin, Italy.
Abstract:
p27/kip1 regulates the G1-S transition of the cell cycle by inhibiting cyclin D-CDK4, cyclin E-CDK2, and cyclin A-CDK2. Modulation of p27 cellular abundance occurs mainly at post-translational level by the ubiquitin-proteasome proteolysis. Although rearrangements and mutations of p27/kip1 are extremely rare events, p27 levels are reduced and associated with a poor prognosis in many human carcinomas. In astrocytic tumors, p27 decreases with advancing anaplasia and is almost absent in glioblastomas. To verify whether the degradation of p27 protein was responsible for its reduced levels in malignant gliomas, p27 degradation activity was tested in 22 tissue extracts that represented high, low, and absent p27 protein levels. p27 protein expression was detected by immunohistochemistry and immunoblot analysis and comparable results between the 2 methods were obtained. Low or undetectable p27 degradation activity was found in samples that displayed high levels of p27, i.e. all 4 normal brain biopsies, and 4 out of 6 grade II astrocytomas. Enhanced degradation activity resulted in malignant gliomas with low or absent p27 protein levels. The proteasome inhibitor LLnL abolished p27 degradation, demonstrating that it occurs in a proteasome-dependent manner. These data suggest that proteasome degradation of p27 may be instrumental in the deregulation of the cell cycle and to the malignant transformation of gliomas.
Insights
Reduced levels of p27 protein in malignant gliomas are linked to increased proteasome degradation. This accelerated degradation of p27 (a cell cycle regulator) contributes to glioma progression and malignant transformation.
Area of Science:
- Molecular Biology
- Oncology
- Cell Cycle Regulation
Background:
- p27/kip1 is a key regulator of the G1-S cell cycle transition, inhibiting cyclin-CDK complexes.
- p27 cellular abundance is primarily controlled by ubiquitin-proteasome degradation.
- Reduced p27 levels correlate with poor prognosis in human carcinomas, including astrocytic tumors where it decreases with advancing grade.
Purpose of the Study:
- To investigate if enhanced protein degradation contributes to reduced p27 levels in malignant gliomas.
- To determine the role of the proteasome pathway in p27 downregulation in gliomas.
Main Methods:
- Immunohistochemistry and immunoblot analysis were used to assess p27 protein expression in 22 glioma tissue extracts.
- p27 degradation activity was measured in tissue extracts representing varying p27 protein levels.
- The effect of the proteasome inhibitor LLnL on p27 degradation was evaluated.
Main Results:
- High p27 protein levels in normal brain and low-grade astrocytomas were associated with low or undetectable degradation activity.
- Malignant gliomas with low or absent p27 exhibited enhanced p27 degradation activity.
- LLnL treatment inhibited p27 degradation, confirming its proteasome-dependent nature.
Conclusions:
- Accelerated proteasome-mediated degradation of p27 is a significant factor in the reduced p27 levels observed in malignant gliomas.
- This enhanced degradation of p27 contributes to cell cycle deregulation and malignant transformation in gliomas.
- Targeting proteasome degradation of p27 may offer a therapeutic strategy for glioma treatment.